Appleblossom Cassia (Cassia javanica L.): A Comprehensive Reference
1. Identity: Botanical Name, Taxonomy, and Common Names
The plant known commercially as Appleblossom Cassia bears the accepted scientific name Cassia javanica L. and carries a wide array of common names, including Appleblossom shower, Rainbow shower, Pink cassia, Apple Blossom, Apple-blossom cassia, Apple-blossom senna, Pink shower, Javanese cassia, Pink and white shower, and Pink shower tree. The Royal Horticultural Society additionally lists the common names appleblossom cassia, horse cassia, and liquorice tree as accepted vernacular designations for this species.
The species belongs to the family Fabaceae and the genus Cassia. The genus name Cassia derives from the ancient Hebrew word quetsi'oth, first used by Dioscorides, a physician in ancient Greece (circa 40–90 AD). Linnaeus, the father of taxonomy, was the first to use Cassia to signify members of this genus. The species epithet javanica is the Latin term for Java, where this plant was originally described. A closely related and taxonomically synonymous taxon is Cassia nodosa Buch.-Ham., which is used interchangeably with C. javanica in the scientific literature, particularly in West African and South Asian ethnobotanical contexts. One study conducted in Ghana explicitly treats Cassia nodosa as a synonym of Cassia javanica.
The tree is referred to as "apple blossom cassia" because its dainty pink and white flowers may be easily confused with those of apple trees. It is also known as Java cassia, pink shower, apple blossom tree, rainbow shower tree, and Palawan cherry. Its origin is in Southeast Asia, but it has been extensively grown in tropical areas worldwide as a garden tree owing to its beautiful crimson and pink flower bunches.
2. Botanical Description and Natural Source
Cassia javanica is a fast-growing, deciduous or semi-deciduous tree that flowers in spring and sheds its leaves in the winter months. It has a straight trunk that reaches heights of 25–40 m. The leaves are paripinnate with 12 pairs of elliptical leaves. The flowers range in colour from pale pink to crimson with yellow-coloured stamens and are found in open clusters.
Native to areas from Assam and southern China through Indonesia, the Philippines, and Papuasia, C. javanica has been widely introduced and naturalized in tropical regions worldwide, including the Caribbean, Central America, Africa, Australia, and parts of the United States such as Florida and Hawaii. Cassia javanica is a tropical plant and does not tolerate frost. In ideal conditions it can become invasive and has been declared a weed in Mexico, Nicaragua, and the Dominican Republic.
The tannin-rich bark is gray and smooth, with former branch scars. It has a broad, flat-topped, moderately dense crown with drooping, somewhat brittle branches. Leaves are pinnate, alternate, up to 27 inches long, with pairs of opposite, glossy, elliptical to oblong leaflets. The tree is briefly deciduous around the time of flowering. Aromatic flowers are borne in clusters up to 7 inches long with numerous blooms resembling apple blossoms. Butterflies and other insects are pollinators. Fruits are hard, woody pods up to 2 feet long and about 1 inch or less in diameter, containing multiple brown bean-like seeds used for propagation.
2.1 Plant Parts Used
Multiple parts of C. javanica have been described in medicinal and phytochemical contexts:
- Bark (stem bark) — used in antidiabetic formulations and the subject of antibacterial and toxicological studies
- Leaves — investigated for antiviral, antidiabetic, antioxidant, and anti-inflammatory properties
- Flowers — used in antimicrobial investigations and traditional oral hygiene applications
- Seeds and ripe pods — used as a traditional laxative; a source of seed gum with commercial relevance
2.2 Common Preparation Forms
Historically, Appleblossom Cassia was employed as a natural laxative, harnessing its mild purgative actions to relieve constipation and promote digestive health. Healers prepared infusions from the flowers and leaves to support bowel function, while decoctions were sometimes used to help purify the blood and maintain overall wellness. In modern supplement contexts, the ingredient appears primarily as a dried powdered extract or standardized botanical extract included within nutritional formulation blends. Seeds of related Cassia species are also consumed as decoctions or in tea preparations.
3. Traditional and Historical Use
3.1 Southeast Asia
Appleblossom Cassia, commonly known as Cassia javanica or Pink Shower Tree, has a long-standing history in traditional medicine, particularly in Southeast Asian and Indian herbal practices. Its delicate blossoms and other plant parts have been incorporated into remedies for centuries, valued for their gentle yet effective therapeutic properties.
In Southeast Asian folk medicine, the bark and leaves have been used for their mild laxative and anti-inflammatory properties. The plant is traditionally used in the treatment of fever, cold, gastric pain, constipation, diabetes mellitus, and malaria, and is also used for oral hygiene to stop bad breath. The tree is widely planted at temples and public gathering places in Thailand, Malaysia, and Indonesia for its beauty and shade.
Ripe pods and seeds serve as a traditional laxative in the Malesian region, and bark along with seeds act as antipyretics for fever in Thailand, though their use may induce emesis.
3.2 South Asia (Ayurvedic Tradition)
In Ayurvedic practices, Appleblossom Cassia was appreciated not only for its cleansing abilities but also for its capacity to balance bodily energies and soothe inflammation. The bark of C. javanica is used as one of the ingredients in antidiabetic Ayurvedic formulations. In the folk medicinal history, Cassia plants are used as laxative and purgative agents. In the Ayurveda system of medicine, they are used to cure headache and fever.
3.3 West Africa (Ghana)
In Ghana, Cassia nodosa (synonym: Cassia javanica) is used in preparations targeted towards the cure of malaria, constipation, cold, and fever. The leaves are used in preparations for the treatment of herpes simplex infection.
3.4 The Philippines
In the Philippines, the plant is used medicinally as a substitute for Cassia fistula for treating constipation, colic, chlorosis, and urinary disorders. Its leaves are noted as effective against herpes simplex.
3.5 Egypt and the Middle East
In Egypt, Cassia javanica is widely distributed as an ornamental plant, and these plants are traditionally used for oral hygienic purposes.
3.6 Traditional Compound Formulas
In addition to standalone remedies, Appleblossom Cassia has been a vital component of synergistic herbal combinations. Traditional formulas often paired it with herbs such as senna, licorice, or ginger, enhancing digestive benefits and softening its action for gentle, sustained relief.
4. Key Constituents and Active Compounds
4.1 General Phytochemical Profile
C. javanica contains various phytochemical constituents, mainly anthraquinone glycosides, flavonoids, alkaloids, sterols, tannins, saponins, and reducing sugars in different parts of the plant. Phytochemical screening of the crude methanolic stem extracts of Cassia javanica showed the presence of different classes of organic compounds including alkaloids, tannins, flavonoids, saponins, phlobatanins, steroids, anthraquinone, and cardiac glycoside.
There are various phytochemical classes in the plant, such as anthraquinone glycosides, flavonoids, alkaloids, sterols, tannins, saponins, and volatile oil.
4.2 Anthraquinones
Phytochemical investigations of the genus Cassia demonstrate the presence of more than 200 chemical compounds, including piperidine alkaloids, anthracene derivatives (anthraquinones), and flavonoids. Anthraquinones are considered the principal bioactive class across most members of the genus. Phytochemical screening of Cassia nodosa (syn. C. javanica) revealed the presence of emodin and rhein in the plant. The maximum level of emodin (0.66 mg g–1 dry weight) and rhein (0.30 mg g–1 dry weight) was observed in leaves.
Anthraquinone compounds isolated specifically from Cassia javanica include 1,3,5,8-tetrahydroxy-6-methoxy-2-methylanthraquinone and 1,7-dihydroxy-4,6-dimethoxy-2-methylanthraquinone. Earlier chemical investigations reported the isolation of anthraquinones and terpenoids from C. javanica leaves, as well as the isolation of novel anthraquinones from its stem bark and heartwood (references cited in Wiley Online Library review on genus Cassia, 2020).
4.3 Flavonoids and Polyphenols
Leaves are reported to contain a variety of secondary metabolites such as flavones, sterols, several hydrocarbons, anthraquinones, and glycosides. Among these, flavones, glycosides, and sterols are considered antidiabetic compounds. Total phenolic and total flavonoid content have been quantified across different aerial parts (leaves, bark, flowers, and seeds) in multiple extraction solvents, as described in studies published in the Arabian Journal of Chemistry (2013).
4.4 Other Constituent Classes
Phytochemicals identified in C. nodosa (C. javanica) extracts also include sterols, alkaloids, tannins, glycosides, and coumarins. GC-MS analysis of flower volatile oil revealed the presence of 29 identified compounds representing 100% of the volatile constituents of C. javanica.
4.5 Seed Gum (Galactomannan)
The seeds of C. javanica yield commercially important wood and seed gum. The seed gum of C. javanica is a galactomannan-type polysaccharide, chemically similar to locust bean gum, and has been investigated for its rheological properties and its potential as a food-grade hydrocolloid. The extraction and processing of this gum is relevant because anthraquinone contamination of the gum has been identified as a safety issue requiring removal prior to food use.
5. Mechanisms of Action
5.1 Laxative / Purgative Mechanism
The anthraquinone substances present in Cassia seeds can inhibit the absorption of colon luminal water, increase the water content in the intestinal lumen, and cause diarrhea. Hydroxyanthracene glycosides are not fully absorbed in the upper gastrointestinal tract; they are converted into active aglycones by microflora in the large intestine and additional bacterial enzymes in the colon, which stimulates colonic motility and affects fluid and electrolyte balance in the colon. The fruit of related species such as Cassia fistula — primarily used in constipation management — contains anthraquinone and high mucilage content. These compounds are metabolized by gut bacteria into active agents that stimulate intestinal peristalsis and increase water and electrolyte secretion, softening stool and easing bowel movements.
5.2 Antioxidant Mechanism
Anthraquinone derivatives have demonstrated antiproliferative, anti-inflammatory, metabolic, cardiovascular, antifibrotic, and immunomodulatory effects, consistently reported across diverse preclinical models, targeting pathways such as NF-κB, PI3K/AKT, MAPKs, AMPK, PPARs, NLRP3, and ferroptosis-related axes. Phenolic compounds — including flavonoids and tannins — are understood to donate hydrogen atoms to reactive oxygen species, thereby quenching them (DPPH radical scavenging mechanism documented in studies of C. javanica aerial parts).
5.3 Anti-inflammatory Mechanism
Ethanol extracts of C. javanica aerial parts showed significant and dose-dependent anti-inflammatory effects in in vivo models. The anti-inflammatory activity is generally attributed to polyphenolic constituents — including flavonoids and tannins — that modulate pro-inflammatory mediator cascades, and to anthraquinone derivatives that exert effects on NF-κB and related signalling pathways.
5.4 Antidiabetic Mechanism
Among the leaf constituents, flavones, glycosides, and sterols are considered to be antidiabetic compounds. The presence of these antidiabetic phytochemicals in C. javanica leaves may contribute the observed pharmacological action.
6. Scientific Evidence by Area of Health Use
It is important to note at the outset that essentially all scientific evidence for Cassia javanica currently consists of in vitro (cell-based) and in vivo (animal-based) preclinical studies. No registered, peer-reviewed, controlled clinical trials involving human participants have been identified in the literature for this specific species. Evidence must accordingly be characterized as preliminary and hypothesis-generating rather than conclusive.
6.1 Digestive Health and Laxative Activity
The ripe pods and seeds are used as a traditional laxative. The bark and seeds are used as antipyretics in the treatment of fevers. Scientific characterization of laxative activity in C. javanica specifically has not been the subject of a published controlled human trial. The evidence base for the laxative properties of the genus rests principally on the pharmacological characterization of its anthraquinone glycosides — extrapolated from better-studied congeners such as Cassia fistula and Cassia angustifolia (senna).
Cassia seed preparations have pharmacological effects including liver-clearing and vision-improving, as well as intestinal moisturizing and laxative effects. The differences in the substances that cause non-laxative effects in Cassia seed preparations from different sources are due to variations in the content of emodin, chrysophanol, aloe-emodin, and rhein.
Evidence strength: Traditional use with mechanistic plausibility; no direct human clinical evidence for C. javanica specifically.
6.2 Antidiabetic / Hypoglycemic Activity
The bark of C. javanica is used as one of the ingredients in antidiabetic Ayurvedic formulations. The leaves have been proved to be active against herpes simplex infection.
A preclinical study published in PMC (PMCID: PMC3312727) examined hypoglycemic activity of Cassia javanica leaves in normal and streptozotocin-induced diabetic rats. Parameters studied included blood glucose, serum cholesterol, serum triglycerides, and serum proteins; results were compared with the standard hypoglycemic drug glibenclamide (0.01 g/kg/day). In preliminary phytochemistry, antidiabetic compounds were detected. Unlike acute treatment, sub-acute treatment of the test drug showed highly significant reduction (37.62%) in blood glucose level of diabetic rats in ten days. This effect was considerably less than the standard drug (63.51%). Leaf extracts demonstrated hypoglycemic activity in animal models, reducing blood glucose levels in streptozotocin-induced diabetic rats following sub-acute administration at a dose of 500 mg/kg body weight over 10 days.
Both C. javanica and C. nodosa are described as less explored for therapeutic potential, though leaves of both have recently been reported to be antidiabetic.
Evidence strength: Animal (in vivo) preclinical only; no human clinical trials identified. The dose used in the streptozotocin-rat model (500 mg/kg body weight) is a common pharmacological screening dose with limited direct translational relevance to human supplementation.
6.3 Antioxidant Activity
In a study of Cassia nodosa (syn. C. javanica) ethanolic stem bark extract, the total antioxidant capacity was determined to be 48.49 ± 5.24 g AAE/100 g, with total phenolic content of 28.48 ± 3.13 g GAE/100 g extract. In the DPPH radical scavenging assay, the concentration required for 50% inhibition was found to be 78.71 ± 6.84 µg/mL.
A study published in the Arabian Journal of Chemistry evaluated the antioxidant activities of two plants, Cassia siamea and Cassia javanica. Total phenolic compounds and flavonoid contents were determined. Antioxidant activity of the extracts was measured using scavenging of DPPH, bleaching of β-carotene, and percentage inhibition of H₂O₂.
Evidence strength: In vitro only; demonstrates radical scavenging capacity of plant extracts under laboratory conditions. No human clinical trials identified.
6.4 Anti-inflammatory Activity
For the anti-inflammatory study of C. nodosa (C. javanica), the carrageenan-induced foot edema assay was used. An ED₅₀ value of 8.52 ± 2.83 mg/kg in the anti-inflammatory test indicated that the Cassia nodosa extract administered orally was very active in reducing inflammation.
The anti-inflammatory activity of C. javanica aerial parts was evaluated using the carrageenan induced paw edema method on Wistar albino rats. Ethanol extracts showed significant and dose-dependent anti-inflammatory effects.
Evidence strength: In vivo (rodent) preclinical only; no human clinical trials identified.
6.5 Antimicrobial Activity
Crude anthraquinone compounds isolated from C. nodosa (C. javanica) exhibited significant antimicrobial activity. Crude extracts and their fractions were examined for antibacterial potential against Klebsiella pneumoniae and Proteus mirabilis. The antibacterial assay showed maximum zone of inhibition for the ethyl acetate fraction. The antibacterial assay showed a maximum zone of inhibition for the ethyl acetate fraction — 20 mm against Proteus mirabilis and 18 mm against Klebsiella pneumoniae — in comparison with levofloxacin used as standard (40 mm). For the methanolic crude extract, inhibition zones were recorded as 14 mm against Klebsiella pneumoniae and 22 mm against Proteus mirabilis.
A study of C. javanica flower volatile oils evaluated antimicrobial activity of these volatile oils against specific oral pathogens in comparison to chlorhexidine.
Evidence strength: In vitro (laboratory disc diffusion / MIC methods) only. Inhibition zones observed were notably lower than the standard antibiotic comparator (levofloxacin). No human clinical trials identified.
6.6 Antiviral Activity (Herpes Simplex)
The leaves of C. javanica are effective against herpes simplex. A published study (ResearchGate PMID reference, 2006) describes the isolation of the compound ent-epiafzelechin-(4α→8)-epiafzelechin from C. javanica leaves, which was shown to inhibit herpes simplex virus type 2 (HSV-2) replication. Cassia javanica has reported anti-herpes simplex virus type 2 (anti-HSV-2) activity among its pharmacological properties.
Evidence strength: In vitro and limited preclinical studies only. The identified biflavonoid (ent-epiafzelechin dimer) represents a specific mechanistic finding, but no human clinical translation data exist.
6.7 Antiplasmodial Activity
In an in vitro antiplasmodial activity test, the Cassia nodosa extract showed moderate antiplasmodial activity with an IC₅₀ value of 23.98 ± 2.07 µg/ml. The chloroquine-sensitive Plasmodium falciparum 3D7 strain was used for the antiplasmodial assay.
Evidence strength: In vitro only, against a single chloroquine-sensitive malaria strain. Moderate activity detected; no in vivo animal studies or human trials identified for C. javanica specifically.
6.8 Antifungal Activity
Three anthraquinone compounds — including 1,3,5,8-tetrahydroxy-6-methoxy-2-methylanthraquinone and 1,7-dihydroxy-4,6-dimethoxy-2-methylanthraquinone from Cassia javanica — were successfully isolated. Antifungal assays revealed that a flavonoid compound (Torosflavone D) at 15 ppm exhibited the highest inhibition rate (48.75%) against Fusarium oxysporum f.sp. lycopersici. Meanwhile, 1-hydroxy-3-ethanoate-6,8-dimethoxy-2-methylanthraquinone at the same concentration inhibited Rhizoctonia solani growth by 40.20%.
Evidence strength: In vitro only, against plant-pathogenic fungi. No human clinical relevance has been established.
6.9 Anticancer / Antiproliferative Activity
C. javanica has several reported pharmacological properties including antioxidant, antidiabetic, anti-cancer, and antimicrobial activities. The honey of C. javanica has been reported to have antifungal and anticancer activities. Specific in vitro antiproliferative data for C. javanica extracts against cancer cell lines appear in scattered publications, but detailed, replicated studies are limited.
Evidence strength: Preliminary; in vitro and indirect (honey-derived) data only. No human clinical evidence identified.
7. Body Systems and Health Areas Associated with Appleblossom Cassia
- Gastrointestinal system: Laxative, purgative, bowel regularity support (traditional and mechanistically plausible; no human clinical trials for C. javanica specifically)
- Metabolic / Endocrine system: Blood glucose modulation, antidiabetic (preclinical animal models)
- Immune / Inflammatory system: Anti-inflammatory (in vivo rodent models); antioxidant (in vitro)
- Infectious disease (microbial): Antibacterial, antifungal, antiviral (HSV-2), antiplasmodial (all in vitro)
- Oral health: Traditional use for bad breath and oral hygiene; in vitro data against oral pathogens
- Dermatological: Traditional use for skin infections; antiviral leaf preparations
8. Dosage Forms and Dosages Reported in Studies
No standardized human clinical dosage for Cassia javanica dietary supplement use has been established by any regulatory or pharmacopoeial authority identified in the available literature. The following dosages appear exclusively in preclinical experimental contexts:
- Leaf extracts administered at 500 mg/kg body weight over 10 days in streptozotocin-induced diabetic rats demonstrated a 37.62% reduction in blood glucose.
- An ED₅₀ value of 8.52 ± 2.83 mg/kg was reported for anti-inflammatory activity in the carrageenan-induced edema model (oral route, rats).
- Antibacterial MIC studies used concentrations in the range of 93.7–187.5 µg/mL against target pathogens in in vitro disc diffusion assays (Royal Society Open Science, 2022).
- Antiplasmodial IC₅₀ was recorded at 23.98 ± 2.07 µg/mL in vitro against P. falciparum 3D7 (Wiley Journal of Chemistry, 2020).
In traditional preparation contexts, healers prepared infusions from the flowers and leaves; decoctions from plant material were also used. No specific traditional preparation volumes or doses are documented in peer-reviewed ethnobotanical publications for this species.
9. Safety Considerations
9.1 Anthraquinone-Related Concerns
The plant contains anthraquinone glycosides, which contribute to its laxative effects but necessitate caution due to potential toxicity. The presence of emodin in Cassia species has prompted considerable attention from a toxicological perspective, as prolonged or high-dose exposure to anthraquinone-rich preparations has been linked to safety concerns. As a result, Cassia-derived materials are frequently discussed in the context of both therapeutic potential and risk assessment.
Overdose of anthraquinone laxatives results in intestinal pain and severe diarrhea with consequent electrolyte imbalance and dehydration. The carcinogenicity of emodin has been studied with equivocal results. As with other laxatives, use in patients with fecal compaction, intestinal obstruction, and undiagnosed abdominal pain is contraindicated. Anthranoid metabolites may be excreted in breast milk.
9.2 Seed Gum and Anthraquinone Contamination
In order to provide a cassia hydrocolloid that can be safely used for food, fodder, pharmaceutical, and personal care purposes, it is imperative that the hydrocolloid be substantially free of potentially hazardous anthraquinones. This is a recognized food-safety issue for seed gum derived from Cassia species, relevant to the industrial use of cassia gum as a food additive.
9.3 Preclinical Toxicological Evaluation of C. nodosa (syn. C. javanica)
Reports of suspected toxicity and adverse events for Cassia species exist in the literature. These reactions may be due to side effects, overdose, or the presence of toxic compounds in the plant extracts. Reports of renal and hepatotoxicity of herbal preparations have been on the increase.
Acute toxicity, liver and kidney function tests, and behavioral changes in the murine model have been used to evaluate toxicity of C. nodosa/C. javanica extracts. Consumption of medicinal plants without evaluating their efficacy and safety profile can result in toxic effects that may affect different organs. The liver and kidneys are the first targets because they are involved in the metabolism and excretion of chemical compounds.
9.4 Emetic Potential
Bark along with seeds used as antipyretics for fever in Thailand may induce emesis. This emetic potential has been noted in traditional use contexts and is relevant to safety characterization of the crude plant material.
9.5 Pharmacokinetic Limitations of Anthraquinones
Clinical development of anthraquinone-based compounds has been limited by unfavorable absorption, distribution, metabolism, and excretion (ADME) characteristics, including poor aqueous solubility, extensive first-pass glucuronidation, and active efflux via intestinal and hepatic transporters. These features are relevant to the bioavailability of active constituents from C. javanica extracts when taken orally.
9.6 Absence of Human Safety Data
No systematic human safety studies or registered clinical trials specifically assessing the safety profile, tolerability, pharmacokinetics, or drug interaction potential of Cassia javanica as a dietary supplement ingredient have been identified in the peer-reviewed literature. Comprehensive human studies are needed to confirm its efficacy and safety.
10. Regulatory and Pharmacopoeial Status
Cassia javanica is not the subject of a dedicated monograph in the WHO Traditional Medicine monograph series, the European Pharmacopoeia, or the Commission E monographs (which cover related species such as Cassia angustifolia/senna). The genus Cassia, with approximately 500 species, is a large group of flowering plants in the family Fabaceae. Cassia species are widely distributed throughout different regions, mainly tropical Asia, North America, and East Africa. Cassia plants exhibit pharmacological activities at large scales such as antimicrobial, anticancer, anti-inflammatory, antioxidant, hypoglycemic, antimutagenic, and antiviral. However, these characterizations apply at the genus level and are not specific regulatory designations for C. javanica.
11. Summary of Evidence Landscape
Cassia javanica (Appleblossom Cassia) is a botanically well-characterized tropical tree with a documented history of medicinal use across Southeast Asia, South Asia, West Africa, and the Philippines. Its pharmacologically active constituents — principally anthraquinone glycosides (emodin, rhein, and novel methylanthraquinones), flavonoids, tannins, alkaloids, and sterols — have been identified through phytochemical screening of multiple plant parts. The mechanistic basis for its traditional laxative use is well-supported by the known pharmacology of hydroxyanthraquinone glycosides, which stimulate colonic motility via bacterial metabolic activation. Preliminary preclinical data support antioxidant, anti-inflammatory, antidiabetic, antibacterial, antifungal, and antiviral activities in cell-based and animal models.
Nevertheless, the evidence base for therapeutic or dietary supplement use in humans remains nascent. No controlled clinical trials in human participants have been published for Cassia javanica specifically. The absence of human pharmacokinetic data, the toxicological concerns associated with chronic anthraquinone exposure, and the gap between in vitro/animal model doses and plausible human supplement doses all represent significant limitations. The inclusion of the ingredient in products reflects a growing interest in botanicals with traditional roots and promising, though not yet fully established, health benefits. Continued research will help clarify its role and potential in modern nutrition.
References
Go back